Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 18
2007 37
2008 102
2009 151
2010 193
2011 175
2012 199
2013 206
2014 237
2015 201
2016 161
2017 144
2018 125
2019 124
2020 131
2021 119
2022 81
2023 73
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,224 results

Results by year

Filters applied: . Clear all
Page 1
Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
Deeks ED. Deeks ED. Drugs. 2017 Oct;77(16):1789-1795. doi: 10.1007/s40265-017-0827-9. Drugs. 2017. PMID: 29071467 Review.
In combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults, once-daily raltegravir 1200 mg provided virological suppression non-inferior to that seen with twice-daily raltegravir 400 mg over 48 and 96 weeks in the phase 3 ONCEMRK trial …
In combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults, once-daily raltegravir 1200 mg provided vi …
A safety evaluation of raltegravir for the treatment of HIV.
de Miguel R, Montejano R, Stella-Ascariz N, Arribas JR. de Miguel R, et al. Expert Opin Drug Saf. 2018 Feb;17(2):217-223. doi: 10.1080/14740338.2018.1411903. Epub 2017 Dec 5. Expert Opin Drug Saf. 2018. PMID: 29199485 Review.
Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. ...Areas covered: Pharmacologic, safety and efficacy data of RAL from clinical trials and post-commercialization published reports are hereby summarized aft …
Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. ...Areas covered …
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.
Richetta C, Tu NQ, Delelis O. Richetta C, et al. Viruses. 2022 Nov 22;14(12):2591. doi: 10.3390/v14122591. Viruses. 2022. PMID: 36560595 Free PMC article. Review.
Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatmen …
Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency vi …
Raltegravir in patients with tuberculosis.
Pozniak A, Meintjes G. Pozniak A, et al. Lancet Infect Dis. 2021 Jun;21(6):748-749. doi: 10.1016/S1473-3099(20)30937-3. Epub 2021 Mar 2. Lancet Infect Dis. 2021. PMID: 33667407 No abstract available.
HIV resistance to raltegravir.
Clavel F. Clavel F. Eur J Med Res. 2009 Nov 24;14 Suppl 3(Suppl 3):47-54. doi: 10.1186/2047-783x-14-s3-47. Eur J Med Res. 2009. PMID: 19959417 Free PMC article. Review.
Similar to all antiretroviral drugs, failure of raltegravir-based treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug. ...Therefore, all HIV-1 subtypes and groups, together with HIV-2, are naturally …
Similar to all antiretroviral drugs, failure of raltegravir-based treatment regimens to fully supress HIV replication almost invariab …
Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
Blonk M, Colbers A, Poirters A, Schouwenberg B, Burger D. Blonk M, et al. Antimicrob Agents Chemother. 2012 Oct;56(10):5070-5. doi: 10.1128/AAC.00672-12. Epub 2012 Jul 16. Antimicrob Agents Chemother. 2012. PMID: 22802250 Free PMC article. Clinical Trial.
Pharmacokinetic sampling of raltegravir was performed up to 12 h after intake on an empty stomach. ...Ginkgo biloba did not reduce raltegravir exposure. The potential increase in the C(max) of raltegravir is probably of minor importance, given the large inter …
Pharmacokinetic sampling of raltegravir was performed up to 12 h after intake on an empty stomach. ...Ginkgo biloba did not reduce …
Raltegravir demonstrates potency.
[No authors listed] [No authors listed] AIDS Patient Care STDS. 2007 Apr;21(4):288. AIDS Patient Care STDS. 2007. PMID: 17506141 No abstract available.
Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.
Townsend CL, O'Rourke J, Milanzi E, Collins IJ, Judd A, Castro H, Vicari M, Jesson J, Leroy V, Renaud F, Penazzato M. Townsend CL, et al. J Int AIDS Soc. 2022 Nov;25(11):e25970. doi: 10.1002/jia2.25970. J Int AIDS Soc. 2022. PMID: 36377082 Free PMC article. Review.
Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We conducted a systematic review to assess the effectiveness and safety of dolutegravir and raltegravir in children and adolescents living with HIV, aged 0-19 …
Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We conducted a systematic …
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.
Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Bettonte S, et al. Eur J Drug Metab Pharmacokinet. 2023 Jul;48(4):353-362. doi: 10.1007/s13318-023-00833-9. Epub 2023 Jun 6. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37278880 Free PMC article.
OBJECTIVE: The aim of this study was to evaluate the onset and disappearance of dolutegravir [uridine diphosphate glucuronosyltransferase (UGT) 1A1 and cytochrome P450 (CYP) 3A4 substrate] and raltegravir (UGT1A1 substrate) induction with strong and moderate inducers using …
OBJECTIVE: The aim of this study was to evaluate the onset and disappearance of dolutegravir [uridine diphosphate glucuronosyltransferase (U …
2,224 results